Form 4: Tarsus Director Sells Over 27,000 Shares

Tarsus Pharmaceuticals Director William J. Link, PhD, sold 27,116 shares of common stock for approximately $1.5 million in a pre-planned transaction.

Summary

• Director William J. Link, PhD, of Tarsus Pharmaceuticals, Inc. (TARS) sold 27,116 shares of common stock.
• The transaction occurred on September 8, 2025, at a weighted average price of $57.00 per share.
• The shares were sold in multiple transactions with prices ranging from $56.66 to $57.45 per share.
• The sale was executed pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
• Following the sale, Dr. Link directly owns 143,332 shares and indirectly owns 10,446 shares through Link Family Enterprise, LP.

Sentiment

Score: 4

Explanation: A director selling shares, even if pre-planned, can be viewed with slight caution by investors. However, the 10b5-1 plan mitigates the negative perception, suggesting a neutral to slightly cautious sentiment rather than outright negative.

Positives

• The sale was conducted under a Rule 10b5-1(c) plan, indicating it was pre-scheduled and not a reaction to recent negative company developments, which can mitigate concerns about insider knowledge.

Negatives

• A director selling a significant number of shares could be perceived negatively by some investors, potentially signaling a lack of confidence, even if pre-planned.

Industry Context

Insider sales are common across all industries. A pre-planned sale under Rule 10b5-1 is a standard mechanism for insiders to diversify holdings or manage liquidity without implying specific market timing based on non-public information.

Related Party Transactions

• The Reporting Person indirectly beneficially owns 10,446 shares through Link Family Enterprise, LP, where the Reporting Person is the controlling member.

Stakeholder Impact

• Shareholders may interpret the director's sale as a signal, potentially leading to short-term price fluctuations. The disclosure of a 10b5-1 plan helps to mitigate concerns about insider knowledge influencing the timing of the sale.

Key Dates

Recommendation

The sale by a director, while significant in volume, was executed under a pre-arranged 10b5-1 plan. This suggests a planned diversification or liquidity event rather than a reaction to new, undisclosed negative information. Therefore, it does not fundamentally alter the investment thesis for Tarsus Pharmaceuticals, warranting a 'hold' recommendation for existing investors, while new investors should conduct further due diligence beyond this single transaction.

Keywords

Tarsus Pharmaceuticals, TARS, William J. Link, Director, Stock Sale, Insider Trading, Form 4, SEC Filing, Equity Transaction, 10b5-1 plan